The financial burden of breast cancer survival is a hidden cost that deserves our attention. While survival rates are improving, the economic repercussions for those who beat breast cancer are often overlooked.
Dr. Aarushi Dhingra, during her PhD research at the University of Queensland, uncovered a significant and persistent financial strain on breast cancer survivors.
"It's a double-edged sword," she explains. "More people are surviving, but at a cost."
The study, using data from nearly 500 Australian women, reveals a stark reality. Out-of-pocket expenses average around $250 in the month of diagnosis, and a whopping $2000 in the year of diagnosis. This is a substantial financial hit, especially considering the average monthly pay for women in Australia.
But here's where it gets controversial: these costs often continue long after treatment ends. Pharmaceutical costs, including hormone therapy and pain management medications, can remain high for years.
And this is the part most people miss: even with Medicare, there are gaps. Co-payments for medication, the cost of allied health services like physiotherapy and psychology, and the difference between Medicare rebates and provider fees all add up.
"As soon as the diagnosis is made, the financial pressure starts," Dr. Dhingra says. "It's an immediate and ongoing burden."
The study, co-authored by experts from Monash University and the University of Bologna, fills a crucial knowledge gap. It highlights the broad financial impact of breast cancer on survivors and the publicly funded healthcare system.
Professor Brenda Gannon, a health economist, emphasizes the importance of understanding these costs in an ageing population with increasing survival rates due to technological advances.
"The findings could guide policymakers in addressing these cost drivers and developing targeted interventions," she adds.
So, what do you think? Is enough being done to support breast cancer survivors financially? Should there be more focus on the long-term economic impact of cancer treatment? We'd love to hear your thoughts in the comments!
